DDInter119 DDInter481
Armodafinil is the enantiopure of the wakefulness-promoting agent modafinil (Provigil), and is indicated to improve wakefulness in adult patients with excessive sleepiness associated with obstructive sleep apnea (OSA), narcolepsy, or shift work disorder (SWD). Research has shown that armodafinil significantly improves driving simulator performance in patients with SWD. Armodafinil consists of the (−)-R-enantiomer of the racemic modafinil. Armodafinil is produced by the pharmaceutical company Cephalon Inc. (a wholly owned subsidiary of Teva Pharmaceutical Industries Ltd.) and was approved by the U.S. Food and Drug Administration (FDA) in June 2007.
Darolutamide is a nonsteroidal androgen receptor antagonist for the treatment of castrate-resistant, non-metastatic prostate cancer (nmCRPC). This condition occurs in the majority of patients with advanced prostate cancer who have been treated with androgen receptor antagonists. Though prior treatment for prostate cancer has been successful for these patients, the cancer eventually progresses to become resistant to existing therapies. This warrants further treatment. The goal of treatment with darolutamide is to delay the progression of prostate cancer to metastatic disease, increasing quality of life and life expectancy for those with advanced prostate cancer.[A189054,A189063] Darolutamide was developed by Bayer HealthCare Pharmaceuticals Inc. and approved by the FDA on July 30th, 2019.
Darolutamide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Voriconazole
Darolutamide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Larotrectinib
Darolutamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Niraparib
Darolutamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Eslicarbazepine
Darolutamide {u} may lead to a major life threatening interaction when taken with {v} Eluxadoline
Darolutamide {u} may lead to a major life threatening interaction when taken with {v} Berotralstat
Darolutamide may cause a minor interaction that can limit clinical effects when taken with Voriconazole
Darolutamide may cause a minor interaction that can limit clinical effects when taken with Larotrectinib
Darolutamide may cause a moderate interaction that could exacerbate diseases when taken with Niraparib
Darolutamide may cause a moderate interaction that could exacerbate diseases when taken with Eslicarbazepine
Darolutamide may lead to a major life threatening interaction when taken with Eluxadoline
Darolutamide may lead to a major life threatening interaction when taken with Berotralstat